GoAI
Get started
Daxor Corporation logo

Daxor Corporation

DXR

NASDAQHealthcareMedical - Instruments & Supplies

Open in GoAI

Previous close

$10.00

−$0.30 · -2.91%

Aug 21, 4:00 PM ET

DXR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

90

Deep Value

Momentum

35

Weakening

Sentiment

64

Bullish

Risk resilience

43

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Michael Richard Feldschuh
Listed since
Jul 25, 1983
Employees
37

Market position

Day range

Current $10.00

52-week range

Current $10.00

Open
$9.97
Previous close
$10.30
Volume
2.01K
0.51× average
Average volume
3.96K
Average daily volume
Market cap
58.38M USD
Beta
0.27
Market reference 1
50-day average
$10.3062
-2.97% below average
200-day average
$11.3977
-12.26% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
73.64M USD
P/E (TTM)
5.51×
P/B (TTM)
1.1×
P/S (TTM)
388.71×
EV / EBITDA
8.02×
Earnings yield
12.47%
Free cash flow yield
-0.82%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-57.45%
Operating margin
6174.23%
Net margin
6105.29%
Return on equity
19.98%
Return on assets
19.93%
Return on invested capital
20.02%

Financial health

Debt / equity
0×
Current ratio
0×
Altman Z-score
287.52
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends2156%831%-493%-1817%Gross margin, FY2021: 138.30%Gross margin, FY2022: 407.64%Gross margin, FY2023: 99.49%Gross margin, FY2024: 100.00%Gross margin, FY2025: 37.49%Operating margin, FY2021: -181.56%Operating margin, FY2022: -1485.92%Operating margin, FY2023: 0.95%Operating margin, FY2024: 29.16%Operating margin, FY2025: 1824.65%Net margin, FY2021: -181.56%Net margin, FY2022: -1465.41%Net margin, FY2023: 0.81%Net margin, FY2024: 25.17%Net margin, FY2025: 1821.48%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 138.30%. Gross margin FY2022 407.64%. Gross margin FY2023 99.49%. Gross margin FY2024 100.00%. Gross margin FY2025 37.49%. Operating margin FY2021 -181.56%. Operating margin FY2022 -1485.92%. Operating margin FY2023 0.95%. Operating margin FY2024 29.16%. Operating margin FY2025 1824.65%. Net margin FY2021 -181.56%. Net margin FY2022 -1465.41%. Net margin FY2023 0.81%. Net margin FY2024 25.17%. Net margin FY2025 1821.48%.

Income trends

Revenue

503.42K USD-76.37%

Operating income

9.19M USD+1378.18%

Net income

9.17M USD+1609.71%
Income trends across reported periods38.31M USD23.43M USD8.55M USD−6.34M USDRevenue, FY2021: −2.62M USDRevenue, FY2022: −353.36K USDRevenue, FY2023: 34.59M USDRevenue, FY2024: 2.13M USDRevenue, FY2025: 503.42K USDOperating income, FY2021: 4.75M USDOperating income, FY2022: 5.25M USDOperating income, FY2023: 329.74K USDOperating income, FY2024: 621.42K USDOperating income, FY2025: 9.19M USDNet income, FY2021: 4.75M USDNet income, FY2022: 5.18M USDNet income, FY2023: 280.64K USDNet income, FY2024: 536.33K USDNet income, FY2025: 9.17M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 −2.62M USD. Revenue FY2022 −353.36K USD. Revenue FY2023 34.59M USD. Revenue FY2024 2.13M USD. Revenue FY2025 503.42K USD. Operating income FY2021 4.75M USD. Operating income FY2022 5.25M USD. Operating income FY2023 329.74K USD. Operating income FY2024 621.42K USD. Operating income FY2025 9.19M USD. Net income FY2021 4.75M USD. Net income FY2022 5.18M USD. Net income FY2023 280.64K USD. Net income FY2024 536.33K USD. Net income FY2025 9.17M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue503.42K USD2.13M USD34.59M USD−353.36K USD−2.62M USD
Cost of goods sold314.68K USD—177.08K USD1.09M USD1M USD
Gross profit188.74K USD2.13M USD34.41M USD−1.44M USD−3.62M USD
Research and development———−14.65 USD—
Selling, general, and administrative—294.19K USD307.36K USD1.09M USD991.31K USD
Operating expenses−9M USD1.59M USD939.06K USD1.09M USD1.07M USD
Interest income26.69K USD————
Interest expense15.96K USD85.09K USD49.1K USD72.45K USD19.61K USD
Depreciation and amortization—1.44M USD506.82K USD859.73K USD745.58K USD
Operating income9.19M USD621.42K USD329.74K USD5.25M USD4.75M USD
Net income9.17M USD536.33K USD280.64K USD5.18M USD4.75M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
1 beat, 0 misses, 0 met estimates
Average EPS surprise
+32.55%
1 comparable report
Latest EPS result
1.89

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.071.190.31-0.57Q1 '23No estimateQ3 '23No estimateQ1 '24No estimateQ3 '24No estimateQ1 '25No estimateQ3 '25BeatQ1 '26No estimateQ3 '26Estimate
Q1 2023, reported Mar 2, 2023: actual 0.81, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 28, 2023: actual -0.32, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 25, 2024: actual 0.72, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Jul 10, 2024: actual -0.39, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 6, 2025: actual 0.44, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 29, 2025: actual -0.074, estimate -0.11, surprise +32.55%, Beat. Q1 2026, reported Mar 2, 2026: actual 1.89, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 24, 2026: actual —, estimate -0.03, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates43.2M28.8M14.41M15.6KQ1 '23MissQ3 '23MissQ1 '24No estimateQ3 '24No estimateQ1 '25No estimateQ3 '25MissQ1 '26No estimateQ3 '26Estimate
Q1 2023, reported Mar 2, 2023: actual 96.4K USD, estimate 40M USD, surprise -99.76%, Miss. Q3 2023, reported Aug 28, 2023: actual 80.97K USD, estimate 40M USD, surprise -99.80%, Miss. Q1 2024, reported Mar 25, 2024: actual 82.45K USD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Jul 10, 2024: actual 71.76K USD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 6, 2025: actual 695.31K USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 29, 2025: actual 18.35K USD, estimate 1.9M USD, surprise -99.03%, Miss. Q1 2026, reported Mar 2, 2026: actual 131.85K USD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 24, 2026: actual —, estimate 2.8M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$23.00

130.00% upside
Past 12 months12-month forecastHigh $23.00Average $23.00Low $23.00

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

1 institution

DXR news

globenewswire.com

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader…

Read source
globenewswire.com

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader…

Read source
globenewswire.com

Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas

Daxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy Oak Ridge, TN, July 07, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in…

Read source
globenewswire.com

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

New Technology Expands Daxor's Diagnostic Capabilities to Enable Continuous, Remote Tracking of Blood Volume Status Using Wearable Sensors, Enhancing Care for Heart Failure, Syncope, Anemia, and Polycythemia OAK RIDGE,…

Read source

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.20

2012 complete year-86.7% since 2008

Corporate action history

Dividend

Ex-dividend Jan 5, 2018

$0.03

Monthly

Record Jan 8, 2018 · Payment Jan 12, 2018

Dividend

Ex-dividend Dec 20, 2017

$0.03

Annual

Dividend

Ex-dividend Dec 20, 2016

$0.03

Annual

Record Dec 22, 2016 · Payment Dec 29, 2016

Dividend

Ex-dividend Dec 18, 2015

$0.04

Annual

Record Dec 22, 2015 · Payment Dec 29, 2015

Dividend

Ex-dividend Dec 4, 2014

$0.03

Annual

Record Dec 8, 2014 · Payment Dec 26, 2014

Dividend

Ex-dividend Dec 5, 2013

$0.05

Annual

Record Dec 9, 2013 · Payment Dec 27, 2013

DXR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding DXR

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
512.73K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%

Continue in GoAI

Research DXR

research.disclaimer